UPDATE: Barclays Downgrades Seattle Genetics (SGEN) to Equalweight

November 29, 2016 6:39 AM EST
Get Alerts SGEN Hot Sheet
Price: $64.87 -3.08%

Rating Summary:
    7 Buy, 9 Hold, 9 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade SGEN Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
(Updated - November 29, 2016 8:18 AM EST)

Barclays downgraded Seattle Genetics (NASDAQ: SGEN) from Overweight to Equalweight with a price target of $70.00 (from $53.00). Analyst Geoff Meacham said benefit from ALCANZA, ECHELON-1, and CD33A is largely reflected in shares.

For an analyst ratings summary and ratings history on Seattle Genetics click here. For more ratings news on Seattle Genetics click here.

Shares of Seattle Genetics closed at $66.99 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change, Downgrades

Related Entities

Barclays

Add Your Comment